Innate Pharma (IPHA) Research & Development (2019 - 2025)
Innate Pharma (IPHA) reported Research & Development of -$50.8 million for Q4 2025, up 8.59% on a YoY basis from -$46.8 million in Q4 2024, and down 118.6% quarter-over-quarter from -$23.2 million in Q2 2025.
Innate Pharma (IPHA) Research & Development (2019 - 2025) Analysis & Trends
Innate Pharma has reported Research & Development for 7 years, with the latest figure at -$50.8 million in Q4 2025.
- For the quarter ending Q4 2025, Research & Development rose 8.59% year-over-year to -$50.8 million; the trailing twelve-month figure through Dec 2025 stood at -$160.9 million (up 11.31% YoY), and the FY2025 full-year result was $50.8 million, down 8.59% from the prior year.
- Research & Development for Q4 2025 stood at -$50.8 million, down from -$23.2 million in the prior quarter.
- The five-year high for Research & Development was $705703.1 in Q2 2021, with the low at -$60.3 million in Q4 2023.
- Historically, Research & Development has averaged -$33.5 million across 5 years, with a median of -$32.8 million in 2024.
- Annual changes were most pronounced in 2021 — Research & Development surged 102.03% — and 2023, when it slumped 114256.68%.
- Innate Pharma's Research & Development stood at -$53.8 million in 2021, then surged by 99.9% to -$52709.0 in 2022, then slumped by 114256.68% to -$60.3 million in 2023, then grew by 7.85% to -$55.5 million in 2024, then grew by 8.59% to -$50.8 million in 2025.
- The last three Research & Development figures came in at -$50.8 million (Q4 2025), -$23.2 million (Q2 2025), and -$55.5 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | 4.32 Mn |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | 15.66 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 626,092.00 |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | -101.30 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 1.46 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -2.30 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 357,444.00 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 961.60 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -58.00 Mn |
| 10 | Innate Pharma | 194.19 Mn | 194.19 Mn | - | -50.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -50.78 Mn |
| Jun 30, 2025 | -23.23 Mn |
| Dec 31, 2024 | -55.55 Mn |
| Jun 30, 2024 | -31.31 Mn |
| Dec 31, 2023 | -60.28 Mn |
| Jun 30, 2023 | -34.25 Mn |
| Dec 31, 2022 | -52,709.04 |
| Jun 30, 2022 | -26.63 Mn |
| Dec 31, 2021 | -53.77 Mn |
| Jun 30, 2021 | 705,703.06 |
| Dec 31, 2020 | -59.27 Mn |
| Jun 30, 2020 | -34.69 Mn |
| Dec 31, 2019 | -87.27 Mn |
| Jun 30, 2019 | -41.11 Mn |